Thiazolidinediones use reduces risk of rheumatoid arthritis in type 2 diabetes patients
Written By : Aditi
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-12-25 11:30 GMT | Update On 2023-12-26 05:40 GMT
Advertisement
China: A study published in Arthritis Care & Research by a team led by Houyu Zhao, PhD from the School of Public Health, Peking University, concluded that T2DM patients who use thiazolidinediones have a lower risk of developing rheumatoid arthritis.
Thiazolidinediones (TZDs) have demonstrated a potential protective effect against rheumatoid arthritis (RA) in preclinical studies. However, there needs to be more evidence from population-based studies.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.